Ravi Salgia to Carcinoma, Renal Cell
This is a "connection" page, showing publications Ravi Salgia has written about Carcinoma, Renal Cell.
Connection Strength
1.142
-
Responses to Alectinib in ALK-rearranged Papillary Renal Cell Carcinoma. Eur Urol. 2018 07; 74(1):124-128.
Score: 0.478
-
Expression of the EPHB4 receptor tyrosine kinase in head and neck and renal malignancies--implications for solid tumors and potential for therapeutic inhibition. Growth Factors. 2014 Dec; 32(6):202-6.
Score: 0.372
-
Twelve-Month Follow-up of the Immune Response After COVID-19 Vaccination in Patients with Genitourinary Cancers: A Prospective Cohort Analysis. Oncologist. 2023 09 07; 28(9):e748-e755.
Score: 0.171
-
Initial clinical sensitivity and acquired resistance to MET inhibition in MET-mutated papillary renal cell carcinoma. J Clin Oncol. 2013 Jun 01; 31(16):e254-8.
Score: 0.083
-
Infectious complications of immune checkpoint inhibitors in solid organ malignancies. Cancer Med. 2022 01; 11(1):21-27.
Score: 0.038